Regulation of tissue- and stimulus-specific cell fate decisions by p53 in vivo

Journal of Pathology

Volumn 223, Issue 2, 2011, Pages 127-137

  Jackson, James G ^a   Post, Sean M ^a   Lozano, Guillermina ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

apoptosis; cell cycle arrest; genotoxic stress; mouse; radiation; senescence

Indexed keywords

PROTEIN P21; PROTEIN P53;

APOPTOSIS; CANCER INHIBITION; CELL AGING; CELL CYCLE ARREST; CELL DEATH; CELL FATE; CELL HYPOXIA; CELL PROLIFERATION; CELL STIMULATION; CELL STRESS; CELL SURVIVAL; DNA DAMAGE; HUMAN; IN VIVO CULTURE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REGULATORY MECHANISM; REVIEW;

EID: 78650018910     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.2783     Document Type: Review

References (126)

1. Lowe SW, Cepero E, Evan G,. Intrinsic tumour suppression. Nature 2004; 432: 307-315.
2. Kastan MB, Bartek J,. Cell-cycle checkpoints and cancer. Nature 2004; 432: 316-323.
3. Gudkov AV, Komarova EA,. The role of p53 in determining sensitivity to radiotherapy. Nature Rev Cancer 2003; 3: 117-129.
4. Gottlieb E, Haffner R, King A, et al., Transgenic mouse model for studying the transcriptional activity of the p53 protein: age- and tissue-dependent changes in radiation-induced activation during embryogenesis. EMBO J 1997; 16: 1381-1390.
5. Komarova EA, Chernov MV, Franks R, et al., Transgenic mice with p53-responsive lacZ: p53 activity varies dramatically during normal development and determines radiation and drug sensitivity in vivo. EMBO J 1997; 16: 1391-1400.
6. Midgley CA, Owens B, Briscoe CV, et al., Coupling between gamma irradiation, p53 induction and the apoptotic response depends upon cell type in vivo. J Cell Sci 1995; 108: 1843-1848.
7. MacCallum DE, Hupp TR, Midgley CA, et al., The p53 response to ionising radiation in adult and developing murine tissues. Oncogene 1996; 13: 2575-2587.
8. Riley T, Sontag E, Chen P, et al., Transcriptional control of human p53-regulated genes. Nature Rev Mol Cell Biol 2008; 9: 402-412.
9. Bouvard V, Zaitchouk T, Vacher M, et al., Tissue and cell-specific expression of the p53-target genes: bax, fas, mdm2 and waf1/p21, before and following ionising irradiation in mice. Oncogene 2000; 19: 649-660.
10. Coates PJ, Lorimore SA, Lindsay KJ, et al., Tissue-specific p53 responses to ionizing radiation and their genetic modification: the key to tissue-specific tumour susceptibility? J Pathol 2003; 201: 377-388.
11. Fei P, Bernhard EJ, El-Deiry WS,. Tissue-specific induction of p53 targets in vivo. Cancer Res 2002; 62: 7316-7327.
12. Burns TF, Bernhard EJ, El-Deiry WS,. Tissue specific expression of p53 target genes suggests a key role for KILLER/DR5 in p53-dependent apoptosis in vivo. Oncogene 2001; 20: 4601-4612.
13. Lowe SW, Schmitt EM, Smith SW, et al., p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature 1993; 362: 847-849.
14. Clarke AR, Purdie CA, Harrison DJ, et al., Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature 1993; 362: 849-852.
15. Lee Y, Chong MJ, McKinnon PJ,. Ataxia telangiectasia mutated-dependent apoptosis after genotoxic stress in the developing nervous system is determined by cellular differentiation status. J Neurosci 2001; 21: 6687-6693.
16. Lang GA, Iwakuma T, Suh YA, et al., Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome. Cell 2004; 119: 861-872.
17. Kemp CJ, Wheldon T, Balmain A,. p53-deficient mice are extremely susceptible to radiation-induced tumorigenesis. Nature Genet 1994; 8: 66-69.
18. Westphal CH, Rowan S, Schmaltz C, et al., atm and p53 cooperate in apoptosis and suppression of tumorigenesis, but not in resistance to acute radiation toxicity. Nature Genet 1997; 16: 397-401.
19. Komarov PG, Komarova EA, Kondratov RV, et al., A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy. Science 1999; 285: 1733-1737.
20. Yu H, Shen H, Yuan Y, et al., Deletion of Puma protects hematopoietic stem cells and confers long-term survival in response to high-dose gamma-irradiation. Blood 2010; 115: 3472-3480.
21. Domen J, Gandy KL, Weissman IL,. Systemic overexpression of BCL-2 in the hematopoietic system protects transgenic mice from the consequences of lethal irradiation. Blood 1998; 91: 2272-2282.
22. Vousden KH, Lu X,. Live or let die: the cell's response to p53. Nature Rev Cancer 2002; 2: 594-604.
23. Vousden KH,. Outcomes of p53 activation-spoilt for choice. J Cell Sci 2006; 119: 5015-5020.
24. Johnson SM, Torrice CD, Bell JF, et al., Mitigation of hematologic radiation toxicity in mice through pharmacological quiescence induced by CDK4/6 inhibition. J Clin Invest 2010; 120: 2528-2536.
25. Iaquinta PJ, Lees JA,. Life and death decisions by the E2F transcription factors. Curr Opin Cell Biol 2007; 19: 649-657.
26. DeGregori J, Johnson DG,. Distinct and overlapping roles for E2F family members in transcription, proliferation and apoptosis. Curr Mol Med 2006; 6: 739-748.
27. Ben-Porath I, Weinberg RA,. The signals and pathways activating cellular senescence. Int J Biochem Cell Biol 2005; 37: 961-976.
28. Polager S, Ginsberg D,. p53 and E2f: partners in life and death. Nature Rev Cancer 2009; 9: 738-748.
29. Johnson SM, Torrice CD, Bell JF, et al., Mitigation of hematologic radiation toxicity in mice through pharmacological quiescence induced by CDK4/6 inhibition. J Clin Invest 2010; 120: 2528-2536.
30. Sarnow P, Ho YS, Williams J, et al., Adenovirus E1b-58kd tumor antigen and SV40 large tumor antigen are physically associated with the same 54 kd cellular protein in transformed cells. Cell 1982; 28: 387-394.
31. Werness BA, Levine AJ, Howley PM,. Association of human papillomavirus types 16 and 18 E6 proteins with p53. Science 1990; 248: 76-79.
32. Levine AJ,. The common mechanisms of transformation by the small DNA tumor viruses: the inactivation of tumor suppressor gene products: p53. Virology 2009; 384: 285-293.
33. Marine JC, Francoz S, Maetens M, et al., Keeping p53 in check: essential and synergistic functions of Mdm2 and Mdm4. Cell Death Differ 2006; 13: 927-934.
34. Montes de Oca Luna R, Wagner DS, Lozano G,. Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53. Nature 1995; 378: 203-206.
35. Jones SN, Roe AE, Donehower LA, et al., Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53. Nature 1995; 378: 206-208.
36. Chavez-Reyes A, Parant JM, Amelse LL, et al., Switching mechanisms of cell death in mdm2- and mdm4-null mice by deletion of p53 downstream targets. Cancer Res 2003; 63: 8664-8669.
37. Xiong S, Van Pelt CS, Elizondo-Fraire AC, et al., Synergistic roles of Mdm2 and Mdm4 for p53 inhibition in central nervous system development. Proc Natl Acad Sci U S A 2006; 103: 3226-3231.
38. Valentin-Vega YA, Okano H, Lozano G,. The intestinal epithelium compensates for p53-mediated cell death and guarantees organismal survival. Cell Death Differ 2008; 15: 1772-1781.
39. Francoz S, Froment P, Bogaerts S, et al., Mdm4 and Mdm2 cooperate to inhibit p53 activity in proliferating and quiescent cells in vivo. Proc Natl Acad Sci U S A 2006; 103: 3232-3237.
40. Grier JD, Xiong S, Elizondo-Fraire AC, et al., Tissue-specific differences of p53 inhibition by Mdm2 and Mdm4. Mol Cell Biol 2006; 26: 192-198.
41. de Rozieres S, Maya R, Oren M, et al., The loss of mdm2 induces p53-mediated apoptosis. Oncogene 2000; 19: 1691-1697.
42. Ringshausen I, O'Shea CC, Finch AJ, et al., Mdm2 is critically and continuously required to suppress lethal p53 activity in vivo. Cancer Cell 2006; 10: 501-514.
43. Parant J, Chavez-Reyes A, Little NA, et al., Rescue of embryonic lethality in Mdm4-null mice by loss of Trp53 suggests a nonoverlapping pathway with MDM2 to regulate p53. Nature Genet 2001; 29: 92-95.
44. Terzian T, Wang Y, Van Pelt CS, et al., Haploinsufficiency of Mdm2 and Mdm4 in tumorigenesis and development. Mol Cell Biol 2007; 27: 5479-5485.
45. Macleod KF, Sherry N, Hannon G, et al., p53-dependent and independent expression of p21 during cell growth, differentiation, and DNA damage. Genes Dev 1995; 9: 935-944.
46. el-Deiry WS, Tokino T, Velculescu VE, et al., WAF1, a potential mediator of p53 tumor suppression. Cell 1993; 75: 817-825.
47. Xiong Y, Hannon GJ, Zhang H, et al., p21 is a universal inhibitor of cyclin kinases. Nature 1993; 366: 701-704.
48. Noda A, Ning Y, Venable SF, et al., Cloning of senescent cell-derived inhibitors of DNA synthesis using an expression screen. Exp Cell Res 1994; 211: 90-98.
49. Jackson JG, Pereira-Smith OM,. p53 is preferentially recruited to the promoters of growth arrest genes p21 and GADD45 during replicative senescence of normal human fibroblasts. Cancer Res 2006; 66: 8356-8360.
50. Martin-Caballero J, Flores JM, Garcia-Palencia P, et al., Tumor susceptibility of p21(Waf1/Cip1)-deficient mice. Cancer Res 2001; 61: 6234-6238.
51. Wang YA, Elson A, Leder P,. Loss of p21 increases sensitivity to ionizing radiation and delays the onset of lymphoma in atm-deficient mice. Proc Natl Acad Sci U S A 1997; 94: 14590-14595.
52. Merritt AJ, Allen TD, Potten CS, et al., Apoptosis in small intestinal epithelia from p53-null mice: evidence for a delayed, p53-independent G2/M-associated cell death after gamma-irradiation. Oncogene 1997; 14: 2759-2766.
53. Merritt AJ, Potten CS, Kemp CJ, et al., The role of p53 in spontaneous and radiation-induced apoptosis in the gastrointestinal tract of normal and p53-deficient mice. Cancer Res 1994; 54: 614-617.
54. Komarova EA, Kondratov RV, Wang K, et al., Dual effect of p53 on radiation sensitivity in vivo: p53 promotes hematopoietic injury, but protects from gastro-intestinal syndrome in mice. Oncogene 2004; 23: 3265-3271.
55. MacFarlane M, Jones NA, Dive C, et al., DNA-damaging agents induce both p53-dependent and p53-independent apoptosis in immature thymocytes. Mol Pharmacol 1996; 50: 900-911.
56. Tron VA, Trotter MJ, Tang L, et al., p53-regulated apoptosis is differentiation dependent in ultraviolet B-irradiated mouse keratinocytes. Am J Pathol 1998; 153: 579-585.
57. Christophorou MA, Ringshausen I, Finch AJ, et al., The pathological response to DNA damage does not contribute to p53-mediated tumour suppression. Nature 2006; 443: 214-217.
58. Backlund MG, Trasti SL, Backlund DC, et al., Impact of ionizing radiation and genetic background on mammary tumorigenesis in p53-deficient mice. Cancer Res 2001; 61: 6577-6582.
59. Efeyan A, Garcia-Cao I, Herranz D, et al., Tumour biology: policing of oncogene activity by p53. Nature 2006; 443: 159.
60. Weinberg RA,. The retinoblastoma protein and cell cycle control. Cell 1995; 81: 323-330.
61. Sherr CJ, McCormick F,. The RB and p53 pathways in cancer. Cancer Cell 2002; 2: 103-112.
62. Cantley LC, Neel BG,. New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc Natl Acad Sci U S A 1999; 96: 4240-4245.
63. Land H, Parada LF, Weinberg RA,. Tumorigenic conversion of primary embryo fibroblasts requires at least two cooperating oncogenes. Nature 1983; 304: 596-602.
64. Bissonnette RP, Echeverri F, Mahboubi A, et al., Apoptotic cell death induced by c-myc is inhibited by bcl-2. Nature 1992; 359: 552-554.
65. Fanidi A, Harrington EA, Evan GI,. Cooperative interaction between c-myc and bcl-2 proto-oncogenes. Nature 1992; 359: 554-556.
66. Sherr CJ,. Tumor surveillance via the ARF-p53 pathway. Genes Dev 1998; 12: 2984-2991.
67. Symonds H, Krall L, Remington L, et al., p53-dependent apoptosis suppresses tumor growth and progression in vivo. Cell 1994; 78: 703-711.
68. Pierce AM, Gimenez-Conti IB, Schneider-Broussard R, et al., Increased E2F1 activity induces skin tumors in mice heterozygous and nullizygous for p53. Proc Natl Acad Sci U S A 1998; 95: 8858-8863.
69. Agger K, Santoni-Rugiu E, Holmberg C, et al., Conditional E2F1 activation in transgenic mice causes testicular atrophy and dysplasia mimicking human CIS. Oncogene 2005; 24: 780-789.
70. Pierce AM, Fisher SM, Conti CJ, et al., Deregulated expression of E2F1 induces hyperplasia and cooperates with ras in skin tumor development. Oncogene 1998; 16: 1267-1276.
71. Prasad VS, LaFond RE, Zhou M, et al., Upregulation of endogenous p53 and induction of in vivo apoptosis in B-lineage lymphomas of E(mu)-myc transgenic mice by deregulated c-myc transgene. Mol Carcinog 1997; 18: 66-77.
72. Finch AJ, Soucek L, Junttila MR, et al., Acute overexpression of Myc in intestinal epithelium recapitulates some but not all the changes elicited by Wnt/beta-catenin pathway activation. Mol Cell Biol 2009; 29: 5306-5315.
73. Eischen CM, Weber JD, Roussel MF, et al., Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis. Genes Dev 1999; 13: 2658-2669.
74. Pelengaris S, Khan M, Evan GI,. Suppression of Myc-induced apoptosis in beta cells exposes multiple oncogenic properties of Myc and triggers carcinogenic progression. Cell 2002; 109: 321-334.
75. Campisi J,. Cellular senescence as a tumor-suppressor mechanism. Trends Cell Biol 2001; 11: S27-31.
76. Collado M, Serrano M,. Senescence in tumours: evidence from mice and humans. Nature Rev Cancer 2010; 10: 51-57.
77. Hayflick L,. The limited in vitro lifetime of human diploid cell strains. Exp Cell Res 1965; 37: 614-636.
78. Sherr CJ, DePinho RA,. Cellular senescence: mitotic clock or culture shock? Cell 2000; 102: 407-410.
79. Shay JW, Roninson IB,. Hallmarks of senescence in carcinogenesis and cancer therapy. Oncogene 2004; 23: 2919-2933.
80. Dimri GP, Lee X, Basile G, et al., A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc Natl Acad Sci U S A 1995; 92: 9363-9367.
81. Gray-Schopfer VC, Soo JK, Bennett DC,. Comment on 'Absence of senescence-associated beta-galactosidase activity in human melanocytic nevi in vivo'. J Invest Dermatol 2008; 128: 1581; author reply 1583-1584.
82. Cotter MA, Florell SR, Leachman SA, et al., Absence of senescence-associated beta-galactosidase activity in human melanocytic nevi in vivo. J Invest Dermatol 2007; 127: 2469-2471.
83. Kurz DJ, Decary S, Hong Y, et al., Senescence-associated (beta)-galactosidase reflects an increase in lysosomal mass during replicative ageing of human endothelial cells. J Cell Sci 2000; 113: 3613-3622.
84. Lee BY, Han JA, Im JS, et al., Senescence-associated beta-galactosidase is lysosomal beta-galactosidase. Aging Cell 2006; 5: 187-195.
85. Collado M, Serrano M,. The power and the promise of oncogene-induced senescence markers. Nature Rev Cancer 2006; 6: 472-476.
86. Collado M, Gil J, Efeyan A, et al., Tumour biology: senescence in premalignant tumours. Nature 2005; 436: 642.
87. Wang C, Jurk D, Maddick M, et al., DNA damage response and cellular senescence in tissues of aging mice. Aging Cell 2009; 8: 311-323.
88. Herbig U, Ferreira M, Condel L, et al., Cellular senescence in aging primates. Science 2006; 311: 1257.
89. Jeyapalan JC, Ferreira M, Sedivy JM, et al., Accumulation of senescent cells in mitotic tissue of aging primates. Mech Ageing Dev 2007; 128: 36-44.
90. Ressler S, Bartkova J, Niederegger H, et al., p16INK4A is a robust in vivo biomarker of cellular aging in human skin. Aging Cell 2006; 5: 379-389.
91. Janzen V, Forkert R, Fleming HE, et al., Stem-cell ageing modified by the cyclin-dependent kinase inhibitor p16INK4a. Nature 2006; 443: 421-426.
92. Midgley CA, White S, Howitt R, et al., APC expression in normal human tissues. J Pathol 1997; 181: 426-433.
93. Wang Y, Schulte BA, LaRue AC, et al., Total body irradiation selectively induces murine hematopoietic stem cell senescence. Blood 2006; 107: 358-366.
94. CIP1/WAF1 gene in normal diploid human fibroblasts. Science 1997; 277: 831-834.
95. Wei W, Herbig U, Wei S, et al., Loss of retinoblastoma but not p16 function allows bypass of replicative senescence in human fibroblasts. EMBO Rep 2003; 4: 1061-1065.
96. Xue W, Zender L, Miething C, et al., Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature 2007; 445: 656-660.
97. Ventura A, Kirsch DG, McLaughlin ME, et al., Restoration of p53 function leads to tumour regression in vivo. Nature 2007; 445: 661-665.
98. Bodnar AG, Ouellette M, Frolkis M, et al., Extension of life-span by introduction of telomerase into normal human cells. Science 1998; 279: 349-352.
99. Artandi SE, Chang S, Lee SL, et al., Telomere dysfunction promotes non-reciprocal translocations and epithelial cancers in mice. Nature 2000; 406: 641-645.
100. Cosme-Blanco W, Shen MF, Lazar AJ, et al., Telomere dysfunction suppresses spontaneous tumorigenesis in vivo by initiating p53-dependent cellular senescence. EMBO Rep 2007; 8: 497-503.
101. Feldser DM, Greider CW,. Short telomeres limit tumor progression in vivo by inducing senescence. Cancer Cell 2007; 11: 461-469.
102. INK4a. Cell 1997; 88: 593-602.
103. Sarkisian CJ, Keister BA, Stairs DB, et al., Dose-dependent oncogene-induced senescence in vivo and its evasion during mammary tumorigenesis. Nature Cell Biol 2007; 9: 493-505.
104. Swarbrick A, Roy E, Allen T, et al., Id1 cooperates with oncogenic Ras to induce metastatic mammary carcinoma by subversion of the cellular senescence response. Proc Natl Acad Sci U S A 2008; 105: 5402-5407.
105. Courtois-Cox S, Genther Williams SM, Reczek EE, et al., A negative feedback signaling network underlies oncogene-induced senescence. Cancer Cell 2006; 10: 459-472.
106. Davies H, Bignell GR, Cox C, et al., Mutations of the BRAF gene in human cancer. Nature 2002; 417: 949-954.
107. Pollock PM, Harper UL, Hansen KS, et al., High frequency of BRAF mutations in nevi. Nature Genet 2003; 33: 19-20.
108. E600- associated senescence-like cell cycle arrest of human naevi. Nature 2005; 436: 720-724.
109. V600E-induced lung tumors. Genes Dev 2007; 21: 379-384.
110. Bearss DJ, Lee RJ, Troyer DA, et al., Differential effects of p21(WAF1/CIP1) deficiency on MMTV-ras and MMTV-myc mammary tumor properties. Cancer Res 2002; 62: 2077-2084.
111. Lazzerini Denchi E, Attwooll C, Pasini D, et al., Deregulated E2F activity induces hyperplasia and senescence-like features in the mouse pituitary gland. Mol Cell Biol 2005; 25: 2660-2672.
112. Chen Z, Trotman LC, Shaffer D, et al., Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature 2005; 436: 725-730.
113. Acosta JC, O'Loghlen A, Banito A, et al., Chemokine signaling via the CXCR2 receptor reinforces senescence. Cell 2008; 133: 1006-1018.
114. Bartkova J, Rezaei N, Liontos M, et al., Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints. Nature 2006; 444: 633-637.
115. Mallette FA, Gaumont-Leclerc MF, Ferbeyre G,. The DNA damage signaling pathway is a critical mediator of oncogene-induced senescence. Genes Dev 2007; 21: 43-48. (Pubitemid 46089705)
116. Di Micco R, Fumagalli M, Cicalese A, et al., Oncogene-induced senescence is a DNA damage response triggered by DNA hyper-replication. Nature 2006; 444: 638-642.
117. Chang BD, Broude EV, Dokmanovic M, et al., A senescence-like phenotype distinguishes tumor cells that undergo terminal proliferation arrest after exposure to anticancer agents. Cancer Res 1999; 59: 3761-3767.
118. Jackson JG, Pereira-Smith OM,. Primary and compensatory roles for RB family members at cell cycle gene promoters that are deacetylated and downregulated in doxorubicin-induced senescence of breast cancer cells. Mol Cell Biol 2006; 26: 2501-2510.
119. Beausejour CM, Krtolica A, Galimi F, et al., Reversal of human cellular senescence: roles of the p53 and p16 pathways. EMBO J 2003; 22: 4212-4222.
120. Coppe JP, Patil CK, Rodier F, et al., Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor. PLoS Biol 2008; 6: 2853-2868.
121. Kuilman T, Michaloglou C, Vredeveld LC, et al., Oncogene-induced senescence relayed by an interleukin-dependent inflammatory network. Cell 2008; 133: 1019-1031.
122. Wajapeyee N, Serra RW, Zhu X, et al., Oncogenic BRAF induces senescence and apoptosis through pathways mediated by the secreted protein IGFBP7. Cell 2008; 132: 363-374.
123. Komarova EA, Christov K, Faerman AI, et al., Different impact of p53 and p21 on the radiation response of mouse tissues. Oncogene 2000; 19: 3791-3798.
124. Rounbehler RJ, Schneider-Broussard R, Conti CJ, et al., Myc lacks E2F1's ability to suppress skin carcinogenesis. Oncogene 2001; 20: 5341-5349.
125. Mo L, Zheng X, Huang HY, et al., Hyperactivation of Ha-ras oncogene, but not Ink4a/Arf deficiency, triggers bladder tumorigenesis. J Clin Invest 2007; 117: 314-325.
126. Dhomen N, Reis-Filho JS, da Rocha Dias S, et al., Oncogenic Braf induces melanocyte senescence and melanoma in mice. Cancer Cell 2009; 15: 294-303.